DEVONIAN HEALTH GROUP INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.25 CAD | +13.64% |
|
+13.64% | +72.41% |
| Sales 2022 | 2.31M 1.68M 140M | Sales 2023 | 2.35M 1.71M 143M | Capitalization | 39.73M 28.94M 2.42B |
|---|---|---|---|---|---|
| Net income 2022 | -3M -2.19M -182M | Net income 2023 | -4M -2.91M -243M | EV / Sales 2022 | 24.1 x |
| Net cash position 2022 | 3.53M 2.57M 215M | Net cash position 2023 | 1.39M 1.01M 84.47M | EV / Sales 2023 | 16.3 x |
| P/E ratio 2022 |
-15.5
x | P/E ratio 2023 |
-8.09
x | Employees | 7 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.8% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +13.64% | ||
| 1 week | +13.64% | ||
| Current month | +16.28% | ||
| 1 month | +16.28% | ||
| 3 months | +38.89% | ||
| 6 months | +100.00% | ||
| Current year | +72.41% |
1 month
0.22
0.25
Current year
0.130.25
1 year
0.110.28
3 years
0.000.70
5 years
0.000.70
10 years
0.000.95
| Managers | Title | Age | Since |
|---|---|---|---|
Luc Grégoire
CEO | Chief Executive Officer | 64 | 17/23/17 |
Colette Laurin
DFI | Director of Finance/CFO | - | 28/15/28 |
Pascal Brabant
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
André Boulet
CTO | Chief Tech/Sci/R&D Officer | - | 27/15/27 |
Luc Grégoire
CEO | Chief Executive Officer | 64 | 17/23/17 |
Kathryn Gregory
BRD | Director/Board Member | 62 | 28/02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/24/01 | 0.25 | +13.64% | 9,000 |
| 23/24/23 | 0.22 | 0.00% | 8,500 |
Delayed Quote Toronto S.E., May 01, 2024 at 08:27 pm IST
More quotes
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Companyâs flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Companyâs flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis.
Sector
Pharmaceuticals
Calendar
26/06/2024
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +72.41% | 26.93M | |
| +33.25% | 699B | |
| +25.93% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +14.92% | 236B | |
| +4.89% | 198B | |
| -10.18% | 194B | |
| -3.69% | 149B |
- Stock Market
- Equities
- GSD Stock
